Carrie Down1, Natasha Mehta2, Kristen Marks3. 1. 1 New York Presbyterian Hospital , Weill Cornell, New York, New York. 2. 2 Weill Cornell Medical College , New York, New York. 3. 3 New York Presbyterian Hospital , Weill Cornell, Infectious Disease, New York, New York.
Abstract
BACKGROUND: Coinfection with HIV/HCV is associated with more severe liver disease, including increased frequency of steatosis and significant fibrosis, compared to patients mono-infected with HCV or HIV. We sought to explore the impact of steatosis on cardiovascular disease (CVD), liver-related outcomes, and survival. METHODS: An IRB-approved, single-center retrospective cohort study was undertaken to analyze 10-year clinical outcomes in HIV/HCV-coinfected patients. Liver biopsy was performed at study entry for the evaluation of HCV disease; a study pathologist graded samples for fibrosis and steatosis. Clinical outcomes, including cardiac events, liver function with FIB-4, AST to Platelet Ratio Index, and survival were assessed over 10 years. RESULTS: At cohort entry N = 105, mean age 45 ± 7 years, 70% male, and 56% had steatosis present on biopsy. During the 10-year follow-up, no association was found between incident CVD, changes in noninvasive liver fibrosis measures, or survival in the steatosis group compared to nonsteatosis group. However, nonsignificant trends were noted. Overall, mortality for this coinfected population was 25% over 10 years, with liver disease as the most common cause of death. CONCLUSIONS: Given the prevalence of steatosis in approximately half of coinfected patients, larger studies are warranted to determine if steatosis is associated with cardiac disease, diabetes, or liver disease progression in this population. Furthermore, 10-year mortality for this population was very high, underscoring the importance of HCV treatment and need for a better understanding of other variables responsible for decreased survival in this population.
BACKGROUND: Coinfection with HIV/HCV is associated with more severe liver disease, including increased frequency of steatosis and significant fibrosis, compared to patients mono-infected with HCV or HIV. We sought to explore the impact of steatosis on cardiovascular disease (CVD), liver-related outcomes, and survival. METHODS: An IRB-approved, single-center retrospective cohort study was undertaken to analyze 10-year clinical outcomes in HIV/HCV-coinfectedpatients. Liver biopsy was performed at study entry for the evaluation of HCV disease; a study pathologist graded samples for fibrosis and steatosis. Clinical outcomes, including cardiac events, liver function with FIB-4, AST to Platelet Ratio Index, and survival were assessed over 10 years. RESULTS: At cohort entry N = 105, mean age 45 ± 7 years, 70% male, and 56% had steatosis present on biopsy. During the 10-year follow-up, no association was found between incident CVD, changes in noninvasive liver fibrosis measures, or survival in the steatosis group compared to nonsteatosis group. However, nonsignificant trends were noted. Overall, mortality for this coinfected population was 25% over 10 years, with liver disease as the most common cause of death. CONCLUSIONS: Given the prevalence of steatosis in approximately half of coinfected patients, larger studies are warranted to determine if steatosis is associated with cardiac disease, diabetes, or liver disease progression in this population. Furthermore, 10-year mortality for this population was very high, underscoring the importance of HCV treatment and need for a better understanding of other variables responsible for decreased survival in this population.
Authors: Colette Smith; Caroline A Sabin; Jens D Lundgren; Rodolphe Thiebaut; Rainer Weber; Matthew Law; Antonella d'Arminio Monforte; Ole Kirk; Nina Friis-Moller; Andrew Phillips; Peter Reiss; Wafaa El Sadr; Christian Pradier; Signe W Worm Journal: AIDS Date: 2010-06-19 Impact factor: 4.177
Authors: Richard K Sterling; Eduardo Lissen; Nathan Clumeck; Ricard Sola; Mendes Cassia Correa; Julio Montaner; Mark S Sulkowski; Francesca J Torriani; Doug T Dieterich; David L Thomas; Diethelm Messinger; Mark Nelson Journal: Hepatology Date: 2006-06 Impact factor: 17.425
Authors: Juan Berenguer; Francisco X Zamora; Ana Carrero; Miguel A Von Wichmann; Manel Crespo; José López-Aldeguer; Teresa Aldámiz-Echevarría; Marisa Montes; Carmen Quereda; María J Téllez; María J Galindo; José Sanz; Ignacio Santos; Josep M Guardiola; Herminia Esteban; José M Bellón; Juan González-García Journal: J Acquir Immune Defic Syndr Date: 2014-07-01 Impact factor: 3.731
Authors: G Greub; B Ledergerber; M Battegay; P Grob; L Perrin; H Furrer; P Burgisser; P Erb; K Boggian; J C Piffaretti; B Hirschel; P Janin; P Francioli; M Flepp; A Telenti Journal: Lancet Date: 2000-11-25 Impact factor: 79.321
Authors: Gioacchino Leandro; Alessandra Mangia; Jason Hui; Paolo Fabris; Laura Rubbia-Brandt; Guido Colloredo; Luigi E Adinolfi; Tarik Asselah; Julie R Jonsson; Antonina Smedile; Norah Terrault; Valerio Pazienza; Maria Teresa Giordani; Emiliano Giostra; Aurelio Sonzogni; Giuseppe Ruggiero; Patrick Marcellin; Elizabeth E Powell; Jacob George; Francesco Negro Journal: Gastroenterology Date: 2006-05 Impact factor: 22.682
Authors: Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren Journal: Arch Intern Med Date: 2006 Aug 14-28
Authors: Sarah E Sansom; Jonathan Martin; Oluwatoyin Adeyemi; Kerianne Burke; Crystal Winston; Sara Markham; Benjamin Go; Gregory Huhn Journal: Open Forum Infect Dis Date: 2019-03-01 Impact factor: 3.835
Authors: Xiaochen Chen; Xing Liu; Song Duan; Renhai Tang; Sujuan Zhou; Runhua Ye; Yuecheng Yang; Jibao Wang; Shitang Yao; Na He Journal: Int J Environ Res Public Health Date: 2020-12-17 Impact factor: 3.390